News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Optos Plc (OPTS.L) Diabetic Retinopathy Seminar, London


5/15/2014 9:05:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Optos plc (LSE: OPTS), a leading medical retinal imaging company, invites you to a seminar focused on diabetic retinopathy at the offices of Maclay Murray & Spens (One London Wall, EC2Y 5AB) on Thursday 15 May 2014 at 10:15am, with registration and coffee from 10:00am.

Diabetes is a growing health problem with a huge impact on resources. The seminar will include a discussion on the diabetic retinopathy market and offer insight into Optos’ position within this market. The seminar will include a presentation from specialist guest speaker:

Lloyd Paul Aiello,
MD, PhD, Professor of Ophthalmology; Director, Beetham Eye Institute

Lloyd led the team at the Joslin Diabetes Center in a study comparing ultra-widefield imaging to Early Treatment Diabetic Retinopathy Study (ETDRS) protocol fundus photography, the gold standard for assessing severity of diabetic retinopathy.

If you or a colleague would like to attend please could you let us know by emailing Natalie Garland-Collins at Natalie.Garland-Collins@fticonsulting.com or Claire Zoukkari at czoukkari@optos.com

About Diabetic Retinopathy

Diabetic retinopathy is responsible for 4.8% of the 37 million cases of blindness due to eye diseases. Diabetic Retinopathy can be a devastating disease for sufferers. It is estimated that amongst adults it is responsible for 17% of total blindness in parts of the Americas, Europe and the Western Pacific. That figure is expected to rise with the growing obesity epidemic. The risk of losing vision as a result of Diabetic Retinopathy can be halted significantly with prompt identification and treatment of the disease with Pharmaceutical or Photocoagulation therapy. Well-conducted clinical trials have shown that good control of diabetes and hypertension significantly reduces the risk for diabetic retinopathy, and there is evidence from studies spanning more than 30 years that treatment of established retinopathy can reduce the risk for visual loss by more than 90%. Once vision has been lost due to diabetic retinopathy, it usually cannot be restored, although some forms of retinopathy can be treated by complex vitreo-retinal surgery. Screening programs for detecting diabetic retinopathy at a stage at which treatment can prevent visual loss and health education programs are the mainstay of prevention of blindness due to diabetic retinopathy. Care for diabetic retinopathy is relatively expensive and requires properly trained eye-care professionals. The decisions made by each country are adapted to their resources, social expectations and available health-care infrastructure. Effective services for prevention and treatment of diabetic retinopathy can be provided only if adequate medical services for patients with diabetes mellitus are in place.

Natalie Garland-Collins
Senior Consultant, Strategic Communications
FTI Consulting
+44 (0)20 3727 1187
Natalie.Garland-Collins@fticonsulting.com

200 Aldersgate | Aldersgate Street
London, EC1A 4HD
www.fticonsulting.com
@FTI_EMEA

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Optos Plc
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES